cannabis indica

Monoacilglicerol Lipase (MAGL)

termo de indexação original: Monoacylglycerol Lipase (MAGL)

O que é Monoacilglicerol Lipase (MAGL)

A monoacilglicerol lipase, ou MAGL, é a enzima responsável por degradar o 2-AG — cerca de 85% de toda a quebra desse endocanabinoide no cérebro passa por ela. É a contraparte da FAAH, que cuida da anandamida.

A quebra do 2-AG pela MAGL não apenas encerra o sinal canabinoide: libera ácido araquidônico, matéria-prima de prostaglandinas e outros mediadores inflamatórios. Isso dá à enzima um papel duplo, na fronteira entre sinalização endocanabinoide e inflamação — e explica por que inibidores de MAGL são estudados tanto em dor quanto em neuroinflamação.

Estudos com inibidores de MAGL costumam medir o aumento de 2-AG nos tecidos e comparar os efeitos com os de um canabinoide administrado diretamente.

No acervo

O acervo do Cannabis Indica reúne 199 estudos científicos que tocam o composto Monoacilglicerol Lipase (MAGL), publicados entre 2002 e 2024. Pela leitura automatizada, 164 (82%) foram classificados como favoráveis, 31 (16%) como inconclusivos e 4 (2%) como desfavoráveis — uma leitura de máquina, feita para navegar, não para concluir. O desenho mais frequente é metanálise (109 estudos), seguido de estudo em animais (60). As condições mais associadas são Inflamação, Dor e Ansiedade.

Estudos indexados
199
Período coberto
2002–2024
Favoráveis
164 · 82%
Inconclusivos
31 · 16%
Desfavoráveis
4 · 2%
Termo original
Monoacylglycerol Lipase (MAGL)

O acervo em números

Tipo de estudo

Metanálise109
Estudo em Animais60
Estudo Laboratorial18
Ensaio Clínico7
Ensaio Clínico Duplo-Cego4
Metanálise Clínica1

Direção do resultado

Favorável164
Inconclusivo31
Desfavorável4

Por década

2000s10
2010s88
2020s101

199 estudos

Filtrar e buscar no acervo →
  1. 2024

    A systematic review of novel cannabinoids and their targets: Insights into the significance of structure in activity

    InconclusivoMetanáliseAnandamida (AEA)Endocanabinoide (não especificado)+3
  2. 2024

    Cannabinoid Analgesia in Postoperative Pain Management: From Molecular Mechanisms to Clinical Reality

    InconclusivoMetanáliseDorDor — AgudaAnandamida (AEA)Tetraidrocanabinol (THC)+7
  3. 2024

    Editorial: Insights on cannabinoid translational science and medicine: the endocannabinoidome as a target for clinical practice

    FavorávelMetanáliseAnandamida (AEA)Tetraidrocanabinol (THC)+9
  4. 2024

    Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs

    FavorávelMetanáliseAnsiedadeAnandamida (AEA)Endocanabinoide (não especificado)+4
  5. 2024

    Neurolipidomic insights into anxiety disorders: Uncovering lipid dynamics for potential therapeutic advances

  6. 2023

    Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance

  7. 2023

    Cannabinoid Receptor 2 Blockade Prevents Anti-Depressive-like Effect of Cannabidiol Acid Methyl Ester in Female WKY Rats

    FavorávelEstudo em AnimaisDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  8. 2023

    Could cannabinoids provide a new hope for ovarian cancer patients?

  9. 2023

    Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review

  10. 2023

    Regulatory role of the endocannabinoid system on glial cells toward cognitive function in Alzheimer's disease: A systematic review and meta-analysis of animal studies

  11. 2022

    (Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders

  12. 2022

    A review on structurally diversified synthesized molecules as monoacylglycerol lipase inhibitors and their therapeutic uses

    InconclusivoMetanáliseDorCâncerInflamaçãoEndocanabinoide (não especificado)+5
  13. 2022

    Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1

  14. 2022

    Cannabidiol as a personalized treatment for anxiety: clinical cases in Mexico

  15. 2022

    Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study

  16. 2022

    Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection

  17. 2022

    Cannabinoids: Therapeutic Use in Clinical Practice

  18. 2022

    Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review

    FavorávelMetanáliseDorCâncerInflamaçãoAnandamida (AEA)Tetraidrocanabinol (THC)+28
  19. 2022

    Curcumin induces peripheral antinociception by opioidergic and cannabinoidergic mechanism: Pharmacological evidence

  20. 2022

    Differential expression of the neuronal CB1 cannabinoid receptor in the hippocampus of male Ts65Dn Down syndrome mouse model

    FavorávelEstudo em AnimaisSíndrome de DownAnandamida (AEA)Endocanabinoide (não especificado)+3
  21. 2022

    Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia

  22. 2022

    Effect of the MAGL/FAAH Dual Inhibitor JZL-195 on Streptozotocin-Induced Alzheimer's Disease-like Sporadic Dementia in Mice with an Emphasis on Aβ, HSP-70, Neuroinflammation, and Oxidative Stress

  23. 2022

    Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19

  24. 2022

    Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes

    FavorávelEstudo LaboratorialDoenças de PeleAnandamida (AEA)Endocanabinoide (não especificado)+7
  25. 2022

    Endocannabinoid metabolism inhibition ameliorates ovalbumin-induced allergic airway inflammation and hyperreactivity in Guinea pigs

    FavorávelEstudo em AnimaisInflamaçãoAsmaHidrolase de Amidas de Ácidos Graxos (FAAH)
  26. 2022

    Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty

  27. 2022

    Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

  28. 2022

    Endocannabinoid signaling in glioma

  29. 2022

    Enhancing endocannabinoid signalling in astrocytes promotes recovery from traumatic brain injury

  30. 2022

    FABP5 deletion in nociceptors augments endocannabinoid signaling and suppresses TRPV1 sensitization and inflammatory pain

    FavorávelEstudo em AnimaisDorAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  31. 2022

    Footshock-Induced Abstinence from Compulsive Methamphetamine Self-administration in Rat Model Is Accompanied by Increased Hippocampal Expression of Cannabinoid Receptors (CB1 and CB2)

  32. 2022

    Gene Expression Analysis of the Endocannabinoid System in Presymptomatic APP/PS1 Mice

  33. 2022

    Immunomodulatory Role of CB2 Receptors in Emotional and Cognitive Disorders

  34. 2022

    In it together? The case for endocannabinoid–noradrenergic interactions in fear extinction

  35. 2022

    Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study

  36. 2022

    Inhibiting Endocannabinoid Hydrolysis as Emerging Analgesic Strategy Targeting a Spectrum of Ion Channels Implicated in Migraine Pain

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)Endocanabinoide (não especificado)+4
  37. 2022

    Inhibiting the endocannabinoid degrading enzymes FAAH and MAGL during zebrafish embryogenesis alters sensorimotor function

  38. 2022

    Inhibition of monoacylglycerol lipase restrains proliferation, migration, invasion, tumor growth and induces apoptosis in cervical cancer

    FavorávelEstudo LaboratorialCâncerCâncer — Colo do Útero
  39. 2022

    Inhibition of triple negative breast cancer-associated inflammation, tumor growth and brain colonization by targeting monoacylglycerol lipase

    FavorávelEstudo LaboratorialCâncerCâncer — Mama
  40. 2022

    Involvement of the cannabinoid system in chronic inflammatory intestinal diseases: opportunities for new therapies

  41. 2022

    Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

  42. 2022

    Monoacylglycerol Lipase (MAGL) Inhibition Impedes the Osteosarcoma Progression by Regulating Epithelial Mesenchymal Transition

    FavorávelEstudo LaboratorialCâncerCâncer — Ósseo
  43. 2022

    Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study

    FavorávelEnsaio Clínico Duplo-CegoDorInflamaçãoDepressãoTetraidrocanabinol (THC)Canabicromeno (CBC)+2
  44. 2022

    Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice

  45. 2022

    Practical Considerations for the Use of Cannabis in Cancer Pain Management—What a Medical Oncologist Should Know

  46. 2022

    Role of cannabis in inflammatory bowel diseases

  47. 2022

    Role of the endocannabinoid system in the pathophysiology of endometriosis and therapeutic implications

  48. 2022

    Sebaceous immunobiology - skin homeostasis, pathophysiology, coordination of innate immunity and inflammatory response and disease associations

  49. 2022

    Synaptic changes induced by cannabinoid drugs and cannabis use disorder

  50. 2022

    Targeting the Endocannabinoidome in Pancreatic Cancer

  51. 2022

    The Endocannabinoid System and Physical Activity—A Robust Duo in the Novel Therapeutic Approach against Metabolic Disorders

  52. 2022

    The Endocannabinoid System as a Biomarker for Diagnostic and Therapeutic Applications in Depression and Anxiety

  53. 2022

    The Role of Nutritional Status, Gastrointestinal Peptides, and Endocannabinoids in the Prognosis and Treatment of Children with Cancer

    InconclusivoMetanáliseDorCâncerObesidadeAnandamida (AEA)Tetraidrocanabinol (THC)+17
  54. 2022

    The role of the cannabinoid system in fear memory and extinction in male and female mice

    InconclusivoEstudo em AnimaisTEPTAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  55. 2022

    Translation of animal endocannabinoid models of PTSD mechanisms to humans: Where to next?

    FavorávelMetanáliseTEPTAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  56. 2022

    Why Do Marijuana and Synthetic Cannabimimetics Induce Acute Myocardial Infarction in Healthy Young People?

  57. 2021

    Adolescent binge-ethanol accelerates cognitive impairment and β-amyloid production and dysregulates endocannabinoid signaling in the hippocampus of APP/PSE mice

  58. 2021

    Alterations of the endocannabinoid system and its therapeutic potential in autism spectrum disorder

    FavorávelEstudo em AnimaisAutismo2-Araquidonoilglicerol (2-AG)Outros Compostos Relacionados
  59. 2021

    Anticancer Potential of Small-Molecule Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase

  60. 2021

    Cannabinoids—A New Perspective in Adjuvant Therapy for Pulmonary Hypertension

  61. 2021

    Cannabis and Autoimmunity: Possible Mechanisms of Action

  62. 2021

    Cannabis and Inflammation in HIV: A Review of Human and Animal Studies

  63. 2021

    Cannabis sativa: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC

    FavorávelMetanáliseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+17
  64. 2021

    Circulating endocannabinoids and prospective risk for depression in trauma-injury survivors

    InconclusivoMetanáliseDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  65. 2021

    Comorbid anxiety-like behavior in a rat model of colitis is mediated by an upregulation of corticolimbic fatty acid amide hydrolase

  66. 2021

    Endocannabinoid Gene × Gene Interaction Association to Alcohol Use Disorder in Two Adolescent Cohorts

  67. 2021

    Endocannabinoid Metabolism and Traumatic Brain Injury

  68. 2021

    Endocannabinoid Modulation Using Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A Phase 1 Randomized, Placebo-Controlled Study

  69. 2021

    Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review

  70. 2021

    Genetic Variants of Fatty Acid Amide Hydrolase Modulate Acute Inflammatory Responses to Colitis in Adult Male Mice

  71. 2021

    Inhibition of 2-Arachidonoylglycerol Metabolism Alleviates Neuropathology and Improves Cognitive Function in a Tau Mouse Model of Alzheimer's Disease

    FavorávelEstudo em AnimaisDoença de Alzheimer
  72. 2021

    Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models

  73. 2021

    Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12-Week, Randomized, Controlled Study

    DesfavorávelEnsaio Clínico Duplo-CegoTDA e TDAHTiques e Síndrome de TouretteTOCAnandamida (AEA)Tetraidrocanabinol (THC)+1
  74. 2021

    Monoacylglycerol Lipase Inhibition Using JZL184 Attenuates Paw Inflammation and Functional Deficits in a Mouse Model of Inflammatory Arthritis

    FavorávelEstudo em AnimaisArtriteArtrite — Osteoartrite
  75. 2021

    Natural and Synthetic Cannabinoids: Pharmacology, Uses, Adverse Drug Events, and Drug Interactions

  76. 2021

    New Insights in the Involvement of the Endocannabinoid System and Natural Cannabinoids in Nicotine Dependence

  77. 2021

    Pharmacology, Clinical Effects, and Therapeutic Potential of Cannabinoids for Gastrointestinal and Liver Diseases

  78. 2021

    Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition

  79. 2021

    Protective role of endocannabinoid signaling in an animal model of haloperidol-induced tardive dyskinesia

    FavorávelEstudo em AnimaisDistoniaCoreiaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  80. 2021

    Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders

  81. 2021

    Targeting 2-arachidonoylglycerol signalling in the neurobiology and treatment of depression

    FavorávelMetanáliseDepressão2-Araquidonoilglicerol (2-AG)
  82. 2021

    Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models

  83. 2021

    The effects of systemic and local fatty acid amide hydrolase and monoacylglycerol lipase inhibitor treatments on the metabolomic profile of lungs

    FavorávelEstudo em AnimaisInflamaçãoFibroseAsmaHidrolase de Amidas de Ácidos Graxos (FAAH)+1
  84. 2021

    The Endocannabinoid System as Modulator of Exercise Benefits in Mental Health

    FavorávelMetanáliseDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  85. 2021

    The influence of FAAH genetic variation on physiological, cognitive, and neural signatures of fear acquisition and extinction learning in women with PTSD

    FavorávelEnsaio ClínicoTEPTAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  86. 2021

    The Monoacylglycerol Lipase Inhibitor JZL184 Inhibits Lung Cancer Cell Invasion and Metastasis via the CB 1 Cannabinoid Receptor

    FavorávelEstudo em AnimaisCâncerCâncer — Pulmão2-Araquidonoilglicerol (2-AG)
  87. 2021

    The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?

  88. 2020

    An optimized spectrophotometric assay reveals increased activity of enzymes involved in 2-arachidonoyl glycerol turnover in the cerebral cortex of a rat model of Alzheimer's disease

    FavorávelEstudo em AnimaisDoença de Alzheimer2-Araquidonoilglicerol (2-AG)
  89. 2020

    Assessment of boron-containing compounds and oleoylethanolamide supplementation on the recovery trend in patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial

  90. 2020

    Cannabinoids, Endocannabinoids and Sleep

  91. 2020

    Diacylglycerol lipase alpha in astrocytes is involved in maternal care and affective behaviors

    InconclusivoEstudo em AnimaisDepressãoGestação2-Araquidonoilglicerol (2-AG)
  92. 2020

    Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat

  93. 2020

    Effects of the monoacylglycerol lipase inhibitor JZL184 on chickens infected with avian pathogenic Escherichia coli O78: A preliminary pharmacokinetic and infection study

  94. 2020

    Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

  95. 2020

    JZL184, A Monoacylglycerol Lipase Inhibitor, Induces Bone Loss in a Multiple Myeloma Model of Immunocompetent Mice

    InconclusivoEstudo em AnimaisCâncerCâncer — MamaCâncer — Próstata+2
  96. 2020

    Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

  97. 2020

    Neural Stem Cells and Cannabinoids in the Spotlight as Potential Therapy for Epilepsy

    FavorávelMetanáliseEpilepsiaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  98. 2020

    Role of endocannabinoid signaling in a septohabenular pathway in the regulation of anxiety- and depressive-like behavior

    FavorávelEstudo em AnimaisAnsiedadeDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)
  99. 2020

    The Endocannabinoid System Alleviates Pain in a Murine Model of Cancer-Induced Bone Pain

    FavorávelEstudo em AnimaisDorCâncerCâncer — Mama2-Araquidonoilglicerol (2-AG)+2
  100. 2020

    The Endocannabinoid System and Synthetic Cannabinoids in Preclinical Models of Seizure and Epilepsy

  101. 2020

    The Endocannabinoid System May Modulate Sleep Disorders in Aging

  102. 2019

    2-Arachidonoylglycerol Mobilizes Myeloid Cells and Worsens Heart Function After Acute Myocardial Infarction

    InconclusivoEstudo em AnimaisDoenças Cardiovasculares (DCV)Infarto2-Araquidonoilglicerol (2-AG)
  103. 2019

    Cannabinoid Regulation of Fear and Anxiety: an Update

    FavorávelMetanáliseAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  104. 2019

    Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System

  105. 2019

    Endocannabinoid System and the Kidneys: From Renal Physiology to Injury and Disease

  106. 2019

    Endocannabinoid System Components as Potential Biomarkers in Psychiatry

  107. 2019

    Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis

  108. 2019

    Future Aspects for Cannabinoids in Breast Cancer Therapy

  109. 2019

    Hypothalamic endocannabinoid signalling modulates aversive responses related to panic attacks.

    FavorávelEstudo em AnimaisAnsiedadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+5
  110. 2019

    Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome

  111. 2019

    Lower circulating endocannabinoid levels in children with autism spectrum disorder

    InconclusivoMetanáliseAutismoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  112. 2019

    Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer

  113. 2019

    Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity

  114. 2019

    Paradoxical Effects of JZL184, an Inhibitor of Monoacylglycerol Lipase, on Bone Remodelling in Healthy and Cancer-Bearing Mice

  115. 2019

    Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer

  116. 2019

    Repetitive high-frequency transcranial magnetic stimulation reverses depressive-like behaviors and protein expression at hippocampal synapses in chronic unpredictable stress-treated rats by enhancing endocannabinoid signaling

    FavorávelEstudo em AnimaisDepressãoAnandamida (AEA)Endocanabinoide (não especificado)+3
  117. 2019

    Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome

  118. 2019

    The Endocannabinoid System as a Window Into Microglial Biology and Its Relationship to Autism

  119. 2019

    The Endocannabinoid System of Animals

  120. 2018

    2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs.

    FavorávelEstudo em AnimaisEsclerose Múltipla2-Araquidonoilglicerol (2-AG)
  121. 2018

    Cannabinoids and Gastrointestinal Motility: Pharmacology, Clinical Effects, and Potential Therapeutics in Humans

  122. 2018

    Cannabis and pediatric inflammatory bowel disease: change blossoms a mile high.

  123. 2018

    Controlled-Deactivation CB1 Receptor Ligands as a Novel Strategy to Lower Intraocular Pressure.

    FavorávelEstudo em AnimaisGlaucomaTetraidrocanabinol (THC)2-Araquidonoilglicerol (2-AG)+1
  124. 2018

    Effects of repeated long‐term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders.

    FavorávelEstudo em AnimaisAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+4
  125. 2018

    Emerging Role of (Endo)Cannabinoids in Migraine

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  126. 2018

    Endocannabinoids in Body Weight Control

    FavorávelMetanáliseObesidadeAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+6
  127. 2018

    Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver.

    FavorávelEstudo em AnimaisFibroseFibrose — Hepática (Cirrose)
  128. 2018

    Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's disease and Less Well-Known Diseases.

  129. 2018

    MAGL inhibition modulates gastric secretion and motility following NSAID exposure in mice

    FavorávelEstudo em AnimaisÚlcera GástricaEndocanabinoide (não especificado)
  130. 2018

    Median nerve stimulation induces analgesia via orexin-initiated endocannabinoid disinhibition in the periaqueductal gray

    FavorávelEstudo em AnimaisDorDor — Crônica2-Araquidonoilglicerol (2-AG)Acupuntura (MTC)
  131. 2018

    Neuroprotection by (Endo)Cannabinoids in Glaucoma and Retinal Neurodegenerative Diseases

  132. 2018

    Potential of Endocannabinoids to Control Bladder Pain.

    FavorávelMetanáliseCistiteAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  133. 2018

    Role of Endocannabinoids on Sweet Taste Perception, Food Preference, and Obesity-related Disorders

  134. 2018

    Role of the endocannabinoid system in neurological disorders.

    FavorávelMetanáliseAutismoAnandamida (AEA)Endocanabinoide (não especificado)+3
  135. 2018

    The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain

  136. 2018

    Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis.

    FavorávelMetanáliseEsclerose MúltiplaAnandamida (AEA)Tetraidrocanabinol (THC)+9
  137. 2017

    A Pulsed Electromagnetic Field Protects against Glutamate-Induced Excitotoxicity by Modulating the Endocannabinoid System in HT22 Cells

  138. 2017

    Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn’s Disease

  139. 2017

    Cannabinoids and the kidney: effects in health and disease

  140. 2017

    Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?

  141. 2017

    Changes in the Brain Endocannabinoid System in Rat Models of Depression

    InconclusivoEstudo em AnimaisDepressãoAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  142. 2017

    Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?

  143. 2017

    Endocannabinoids: A Promising Impact for Traumatic Brain Injury

  144. 2017

    Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine

    FavorávelMetanáliseEnxaquecaAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  145. 2017

    Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

  146. 2017

    Targeting Cannabinoid Signaling in the Immune System: “High”-ly Exciting Questions, Possibilities, and Challenges.

  147. 2017

    The cannabinoid system and pain.

  148. 2016

    Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome.

  149. 2016

    Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.

  150. 2016

    Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting.

  151. 2016

    Endocannabinoid signaling enhances visual responses through modulation of intracellular chloride levels in retinal ganglion cells.

    FavorávelEstudo em AnimaisCegueira NoturnaAnandamida (AEA)Endocanabinoide (não especificado)+3
  152. 2016

    Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

  153. 2016

    Increased Renal 2-Arachidonoylglycerol Level Is Associated with Improved Renal Function in a Mouse Model of Acute Kidney Injury

  154. 2016

    Inhibition of monoacylglycerol lipase (MAGL) enhances cue-induced reinstatement of nicotine-seeking behavior in mice.

  155. 2016

    Modulation of cellular redox homeostasis by the endocannabinoid system.

  156. 2016

    Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice.

    FavorávelEstudo em AnimaisPruridoHidrolase de Amidas de Ácidos Graxos (FAAH)
  157. 2016

    The endocannabinoid system and bone.

    FavorávelMetanáliseOsteoporoseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  158. 2016

    The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications.

  159. 2016

    The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease.

  160. 2016

    Therapeutic Use of Cannabis in Inflammatory Bowel Disease.

  161. 2015

    Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?

  162. 2015

    Elevated Levels of Endocannabinoids in Chronic Hepatitis C May Modulate Cellular Immune Response and Hepatic Stellate Cell Activation

    InconclusivoEstudo LaboratorialHepatiteAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  163. 2015

    Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture.

    FavorávelEstudo em AnimaisDiabetesAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  164. 2015

    Monoacylglycerol Lipase Regulates Fever Response

    FavorávelEstudo em AnimaisEpilepsiaEpilepsia — FIRES
  165. 2015

    Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  166. 2015

    The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases.

  167. 2014

    A New Generation Fatty Acid Amide Hydrolase Inhibitor Protects Against Kainate-induced Excitotoxicity.

  168. 2014

    Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

  169. 2014

    Endocannabinoid Signaling in Hypothalamic-Pituitary-Adrenocortical Axis Recovery Following Stress: Effects of Indirect Agonists and Comparison of Male and Female Mice.

    FavorávelEstudo em Animais2-Araquidonoilglicerol (2-AG)Canabinoides Sintéticos SR-x+1
  170. 2014

    Experimental Cannabinoid 2 Receptor-Mediated Immune Modulation in Sepsis.

  171. 2014

    In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects

  172. 2014

    Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects

  173. 2014

    Mechanism of platelet activation induced by endocannabinoids in blood and plasma

  174. 2014

    Monoacylglycerol Lipase Inhibitor JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome

    FavorávelEstudo em AnimaisSíndrome de Down2-Araquidonoilglicerol (2-AG)
  175. 2013

    Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment

  176. 2013

    CB1 Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release.

    FavorávelEstudo em AnimaisDiabetesAnandamida (AEA)Endocanabinoide (não especificado)+6
  177. 2013

    Impact of omega-6 polyunsaturated fatty acid supplementation and γ-aminobutyric acid on astrogliogenesis through the endocannabinoid system

    FavorávelEstudo LaboratorialAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+2
  178. 2013

    Mouse Models for Studying Pain In Sickle Disease: Effects of Strain, Age, and Acuteness

    FavorávelEstudo em AnimaisDoença FalciformeCanabinoides Sintéticos CP-x
  179. 2013

    Repeated Low-Dose Administration of the Monoacylglycerol Lipase Inhibitor JZL184 Retains Cannabinoid Receptor Type 1–Mediated Antinociceptive and Gastroprotective Effects

  180. 2013

    Targeting the Endocannabinoid System to Treat Sepsis.

    FavorávelMetanáliseSepseAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+3
  181. 2012

    Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: relevance for in vitro studies with cannabinoids in motor neuron diseases

  182. 2012

    Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice

  183. 2012

    The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity

  184. 2012

    Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome.

    FavorávelEstudo em AnimaisSíndrome do X Frágil2-Araquidonoilglicerol (2-AG)
  185. 2011

    Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes.

  186. 2011

    Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome

  187. 2011

    The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease

  188. 2010

    Do Cannabinoids have a therapeutic role in transplantation?

  189. 2010

    Inhibition of monoacylglycerol lipase by troglitazone, N-arachidonoyl dopamine and the irreversible inhibitor JZL184: comparison of two different assays

    InconclusivoEstudo LaboratorialN-Araquidonoil Dopamina (NADA)
  190. 2009

    Cannabinoids, Endocannabinoids, and Related Analogs in Inflammation

  191. 2009

    Endocannabinoids in the Retina: From Marijuana to Neuroprotection

  192. 2008

    A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner

  193. 2008

    Cannabinoids in pancreatic cancer: Correlation with survival and pain

    FavorávelEstudo LaboratorialCâncerCâncer — PâncreasAnandamida (AEA)2-Araquidonoilglicerol (2-AG)+1
  194. 2008

    Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa

    InconclusivoMetanáliseAnorexia NervosaHidrolase de Amidas de Ácidos Graxos (FAAH)
  195. 2008

    Targeting the endocannabinoid system: to enhance or reduce?

  196. 2007

    Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System.

    FavorávelEstudo em AnimaisDermatite de Contato AlérgicaAnandamida (AEA)Tetraidrocanabinol (THC)+3
  197. 2005

    Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus

    FavorávelEstudo Laboratorial2-Araquidonoilglicerol (2-AG)
  198. 2004

    Endocannabinoids and Their Implications for Epilepsy.

    FavorávelMetanáliseEpilepsiaAnandamida (AEA)Tetraidrocanabinol (THC)+2
  199. 2002

    Brain monoglyceride lipase participating in endocannabinoid inactivation

    InconclusivoEstudo Laboratorial2-Araquidonoilglicerol (2-AG)

Continue por aqui

Perguntas frequentes

Quantos estudos sobre monoacilglicerol lipase (magl) estão indexados no acervo?
São 199 estudos, publicados entre 2002 e 2024. O acervo inteiro tem 7.640 registros.
Que tipos de estudo predominam?
Metanálise: 109 · Estudo em Animais: 60 · Estudo Laboratorial: 18 · Ensaio Clínico: 7 · Ensaio Clínico Duplo-Cego: 4 · Metanálise Clínica: 1. A classificação segue o desenho declarado na fonte.
O que significa a classificação de resultado?
É uma leitura automatizada da conclusão de cada estudo, em três direções — favorável, inconclusivo e desfavorável. Aqui são 164 favoráveis, 31 inconclusivos e 4 desfavoráveis. Serve para navegar o acervo, não para concluir nada clinicamente: a conclusão válida é a do artigo original.

Como citar esta página

ABNT

CANNABIS INDICA. Monoacilglicerol Lipase (MAGL) — estudos científicos sobre cannabis. 2026. Disponível em: https://cannabisindica.com.br/canabinoide/monoacilglicerol-lipase-magl/. Acesso em: 13 set. 2026.

APA

Cannabis Indica. (2026). Monoacilglicerol Lipase (MAGL) — estudos científicos sobre cannabis. https://cannabisindica.com.br/canabinoide/monoacilglicerol-lipase-magl/

Esta página é um índice de acesso. Ao usar um estudo como evidência, cite o artigo original — o link de cada registro leva à fonte.